Clinical trials of new treatments for COVID-19 often do not include vulnerable populations
Studies examining the effectiveness of treatments for COVID-19 often do not include the very populations hardest hit by the disease, according to a new review by University of Chicago Medicine researchers.
The findings, based on an analysis of all US COVID-19 treatment trials registered on ClinicalTrials.gov, were published Jan. 27 in the
Journal of General Internal Medicine.
This study highlights the blind spot in how clinical trials are done in the United States. Researchers, hospitals and pharmaceutical companies need to think hard about their commitment to improving the health of all people.
E-Mail
Studies examining the effectiveness of treatments for COVID-19 often do not include the very populations hardest hit by the disease, according to a new review by University of Chicago Medicine researchers.
The findings, based on an analysis of all US COVID-19 treatment trials registered on ClinicalTrials.gov, were published Jan. 27 in the
Journal of General Internal Medicine. This study highlights the blind spot in how clinical trials are done in the United States, said senior author Neda Laiteerapong, MD, MS, a general internist and associate director of the Center for Chronic Disease Research and Policy at the University of Chicago. Researchers, hospitals and pharmaceutical companies need to think hard about their commitment to improving the health of all people.